Crescendo Biologics Raises $28M To Develop Fully Human Antibody-Fragment Technology
This article was originally published in The Pink Sheet Daily
The U.K. biotech aims to transform the biologics market with its first-in-class human antibody-fragment technology, with mild to moderate psoriasis the lead therapeutic target.
You may also be interested in...
The UK Wellcome Trust Sanger Institute’s latest spin-out has received start-up funding to exploit more than six years of gut bacterial genome sequencing in order to develop novel bacteria-based therapies for a range of diseases.
New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.